Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

4.3K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
4.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

NSAIDs for PI3K-altered head and neck cancer: a biomarker-driven therapeutic opportunity.

Cancer biology & medicine·2026
Same author

Constitutively active MEK1 expression driven by the myeloid-selective MRP8 promoter induces epithelial hyperplasia and papilloma formation.

Biochemical and biophysical research communications·2026
Same author

Patient-derived xenograft models of Fanconi anemia-associated head and neck cancer identify personalized therapeutic strategies.

The Journal of clinical investigation·2025
Same author

Loss of Fanconi anemia proteins causes a reliance on lysosomal exocytosis.

Cell death & disease·2025
Same author

Human Papilloma Virus Does Not Fully Inactivate p53 Cellular Activity in HNSCC.

Head & neck·2025
Same author

Human Papilloma Virus does not fully inactivate p53 cellular activity in HNSCC.

bioRxiv : the preprint server for biology·2025

Related Experiment Video

Updated: Apr 18, 2026

Application of Retinoic Acid to Obtain Osteocytes Cultures from Primary Mouse Osteoblasts
07:13

Application of Retinoic Acid to Obtain Osteocytes Cultures from Primary Mouse Osteoblasts

Published on: May 13, 2014

14.0K

An ATRActive future for differentiation therapy in AML.

Daniel E Johnson1, Robert L Redner1

  • 1Department of Medicine and University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh PA 15213 USA.

Blood Reviews
|January 30, 2015
PubMed
Summary

Differentiation therapy with all-trans retinoic acid (ATRA) shows promise for acute promyelocytic leukemia (APL). However, its effectiveness in non-APL acute myeloid leukemia (AML) is limited, suggesting potential pathway dysfunction.

Keywords:
AMLATRAdifferentiation therapy

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

949
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.8K

Related Experiment Videos

Last Updated: Apr 18, 2026

Application of Retinoic Acid to Obtain Osteocytes Cultures from Primary Mouse Osteoblasts
07:13

Application of Retinoic Acid to Obtain Osteocytes Cultures from Primary Mouse Osteoblasts

Published on: May 13, 2014

14.0K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

949
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.8K

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • All-trans retinoic acid (ATRA) is highly effective in treating acute promyelocytic leukemia (APL) through differentiation therapy.
  • Attempts to extend ATRA's success to non-APL acute myeloid leukemia (AML) have yielded disappointing clinical trial results.
  • Understanding the retinoic acid signaling pathway is crucial for improving AML treatment strategies.

Purpose of the Study:

  • To review the mechanism of retinoic acid signaling in acute myeloid leukemia.
  • To analyze the outcomes of clinical trials incorporating ATRA into non-APL AML regimens.
  • To explore novel strategies targeting retinoic acid signaling dysfunction in AML.

Main Methods:

  • Literature review of retinoic acid signaling mechanisms.
  • Analysis of major clinical trial data for ATRA in non-APL AML.
  • Discussion of preliminary studies on modifying retinoic acid receptor activity.

Main Results:

  • Clinical trials integrating ATRA into non-APL AML treatment have shown limited success.
  • Evidence suggests that the retinoic acid signaling pathway may be impaired in non-APL AML.
  • Preliminary findings indicate that targeting pathways modulating retinoic acid receptor activity could be a viable approach.

Conclusions:

  • The retinoic acid signaling pathway appears dysfunctional in non-APL AML, explaining ATRA's limited efficacy.
  • Strategies aimed at reactivating this pathway by modifying retinoic acid receptor activity show potential.
  • These novel approaches may restore ATRA's ability to induce myeloid differentiation and apoptosis in non-APL AML.